

[Quinine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BC01](#)

EMLc

Indication

Malaria due to Plasmodium falciparum ICD11 code: [1F40](#)

Medicine type

Chemical agent

List type

Core

Additional notes

For use only in the management of severe malaria

Formulations

Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion ; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion (EMLc)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1987 ([TRS 770](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Quinine](#)

DrugBank

[Quinine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of quinine solution for infusion 60 mg/mL to the EMLc for use in the management of severe malaria; - the deletion of quinine tablet 300 mg from the EML and EMLc; - an amendment to the footnote to specify use only in the management of severe malaria; - to modify the formulation descriptions to better describe the available dosage forms.